News | Cardiovascular Surgery | May 04, 2017

Scientists Show How Cells React to Injury From Open-Heart Surgery

Research identifies a new potential way to help cardiac muscle recover from procedures

Scientists Show How Cells React to Injury From Open-Heart Surgery

May 4, 2017 — Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that can be caused by open-heart surgery. The findings point to a new potential way to help these hearts recover more completely.

The cells, known as cardiomyocytes, can be damaged by the process of stopping and starting the heart during surgeries that use cardiopulmonary bypass machines to take over the heart's functions. Hundreds of thousands of these operations are performed each year in the United States to replace failing hearts, bypass clogged arteries, fix leaky valves and more.

While most patients recover easily enough, some patients suffer long-term effects or even fatal heart failure from the stresses of the surgery.

In their study, published in the JCI Insight journal of the American Society for Clinical Investigation, the investigators scrutinized cardiac muscle cells in tissue samples taken from patients before and after open-heart surgeries. Their work demonstrates for the first time in human hearts that cardiac muscle cells react to this type of injury by both destroying and creating new mitochondria, the tiny energy factories inside each cell.

"By accelerating beneficial aspects of this process, doctors one day may be able to speed up healing from open-heart surgery," said Roberta Gottlieb, M.D., director of molecular cardiobiology and professor of medicine at the Cedars-Sinai Heart Institute. She was the principal investigator of the study.

Currently, physicians try to protect the cardiac muscle during open-heart surgery by cooling it and infusing it with potassium to stop its contractions. The goal is to reduce the trauma produced by the one-two punch of first depriving the heart of blood (ischemia) and then flooding it with blood (reperfusion).

"Despite these measures, ischemia/reperfusion injury remains a major cause of complications after heart surgery," said Allen Andres, Ph.D., a research scientist in Gottlieb's laboratory and assistant professor of medicine. He was the first author of the study, working with Robert Mentzer, M.D., professor of medicine, who initiated and designed the study.

Investigators for decades have tried to develop drugs to treat ischemia/reperfusion injury associated with cardiac surgeries, with little success, according to Gottlieb. "There have been wonderful results in animal tests, but not in people," she said. "We need to have a better understanding of the beneficial and deleterious processes that characterize the human heart's response to ischemia and reperfusion."

Prior to beginning the study, the Cedars-Sinai investigative team had expected to find that cardiac muscle cells would dismantle some of the mitochondria after ischemia/reperfusion injury. This process was known to occur in the hearts of laboratory animals. Cells and cell structures in various parts of the body often self-destruct after their genetic material gets damaged by stress or other events. 

The investigators were gratified to confirm that self-destruction of mitochondria occurred in the human heart too. But they were surprised to learn that human cardiac muscle cells also assembled new mitochondria in response to ischemia/reperfusion injury. "We don't know if this mitochondrial production is good or bad news for the heart," Gottlieb said. "These could be better mitochondria or carry genetic defects. We intend to find out."

To learn more, the investigators are developing proposals to collect data on mitochondria from heart transplant patients over a period of months. And they are already investigating a pharmacological agent that shows promise in stimulating mitochondrial creation in animal models.

Researchers from Beaumont Hospital in Dearborn, Mich., and University of Alabama in Birmingham also contributed to this study. Research reported in this publication was supported by the National Institutes of Health under award numbers P01 HL112730, R01 HL132075 and R01 HL103859; and by the American Heart Association.

For more information:

Related Content

Heart and Lung Surgery Patients May Be at High Risk for Opioid Dependence

Image courtesy of the American Heart Association

News | Cardiovascular Surgery | August 22, 2019
The amount of opioids prescribed for patients after heart and lung surgery has a direct relationship with the risk for...
Keck School of Medicine Promotes Patient Diversity in Cardiac Surgery Clinical Trials
News | Cardiovascular Surgery | July 26, 2019
A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung and Blood...
Google Doodle Celebrates Coronary Artery Bypass Graft Pioneer René Favaloro
News | Cardiovascular Surgery | July 12, 2019 | Jeff Zagoudis, Associate Editor
Internet search engine giant Google unveiled a new Doodle on its homepage Friday, July 12, celebrating the life and...
Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease
News | Cardiovascular Surgery | May 03, 2019
Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one...
SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Overlay Init